Scarica l'app Stockscreener
219.91
2.54%
-5.745
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$225.66
Aprire:
$209.775
Volume 24 ore:
9.24M
Relative Volume:
1.49
Capitalizzazione di mercato:
$388.65B
Reddito:
$59.64B
Utile/perdita netta:
$2.36B
Rapporto P/E:
165.94
EPS:
1.3253
Flusso di cassa netto:
$19.68B
1 W Prestazione:
+0.58%
1M Prestazione:
-4.09%
6M Prestazione:
+11.53%
1 anno Prestazione:
+15.78%
Intervallo 1D:
$204.27
$220.03
Intervallo di 1 settimana:
$204.27
$229.78
Portata 52W:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
219.90 | 398.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,094.27 | 898.12B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
235.28 | 561.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
MRK
Merck Co Inc
|
119.48 | 287.52B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
154.05 | 287.55B | 54.45B | 14.42B | 17.15B | 7.333 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie forecasts 9.5% sales growth in 2026 amid blockbuster launches and pipeline momentum - MSN
AbbVie stock slides as investors focus on aesthetics weakness - Crain's Chicago Business
AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth - Benzinga
AbbVie falls as Humira drives Q4 beat, not Rinvoq (ABBV:NYSE) - Seeking Alpha
AMD, AbbVie, Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More Movers - Barron's
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs - marketscreener.com
Eli Lilly, Novo Nordisk, AbbVie: Pharma earnings roundup - Yahoo Finance
ABBV Forecasts Revenue Boost with Favorable Currency Impact - GuruFocus
Earnings call transcript: AbbVie Q4 2025 beats earnings estimates, stock dips - Investing.com
Q4 Earnings Summary: Eli Lilly and AbbVie Beat, Uber Mixed - Investing.com
AbbVie's (ABBV) Growth Prospects Show Strong Momentum - GuruFocus
AbbVie's (ABBV) Anticipated Q1 Revenue Falls Short of Market Exp - GuruFocus
AbbVie Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
AbbVie Raises 2026 Earnings Forecast as Botox Sales Rebound - Bloomberg.com
AbbVie (ABBV) Stock: Slides 6.5% Despite Strong Revenue Growth and 2026 Outlook - CoinCentral
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
These Stocks Are Today’s Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More - Barron's
AbbVie (ABBV) Projects Strong Financial Outlook for Fiscal Year 2026 - GuruFocus
AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. - Barron's
ABBV Plans Continued Investment in Under-Explored Aesthetics Mar - GuruFocus
ABBV Poised for Strong Revenue Growth Through 2029 - GuruFocus
ABBV: Strong Position to Innovate and Positive Business Outlook - GuruFocus
AbbVie's (ABBV) 2026 Profit Forecast Exceeds Wall Street Expecta - GuruFocus
AbbVie (ABBV) Surpasses Earnings and Revenue Expectations - GuruFocus
AbbVie (ABBV) Reports Strong Q4 Earnings, Beating Expectations - GuruFocus
AbbVie (ABBV) Surpasses Q4 Expectations with Strong Humira Sales - GuruFocus
AbbVie (ABBV) Surpasses Q4 Expectations with Strong Earnings - GuruFocus
AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates - Yahoo! Finance Canada
AbbVie Revenue Rises on Immunology Growth - The Wall Street Journal
AbbVie (ABBV) Exceeds Revenue Expectations in Q4 - GuruFocus
AbbVie's 2026 EPS Guidance Excludes Potential IPR&D and Milestone Impacts - GuruFocus
AbbVie beats Q4 expectations, shares dip - Yahoo Finance
AbbVie stock slips despite Q4 beat (ABBV:NYSE) - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Raises 2026 Outlook Despite Q4 Revenue Miss - Chartmill
AbbVie Slumps Despite Quarterly Beat, Solid Guidance - Investor's Business Daily
AbbVie's (NYSE:ABBV) Q4 CY2025: Beats On Revenue - Finviz
(ABBV) AbbVie Expects 2026 Adjusted EPS Range $14.37 to $14.57, vs. FactSet Est of $14.27 - marketscreener.com
AbbVie beats Q4 expectations, shares dip By Investing.com - Investing.com South Africa
AbbVie: Q4 Earnings Snapshot - The Pantagraph
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results - TradingView
AbbVie earnings beat by $0.06, revenue topped estimates By Investing.com - Investing.com South Africa
AbbVie Q4 revenue beats expectations on immunology growth - TradingView
AbbVie earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Earnings Scheduled For February 4, 2026 - Benzinga
AlphaQuest LLC Trims Stock Position in AbbVie Inc. $ABBV - MarketBeat
Savant Capital LLC Has $42.96 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Healthcare Stocks Show Dividend Growth Potential - Intellectia AI
AbbVie: Q4 Financial Highlights - Bitget
AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next - TechStock²
Veteran AbbVie worker accuses company of sidelining her for younger staff - HRD America
AbbVie (ABBV) Set for Earnings Surge with Key Developments Ahead - GuruFocus
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.08%
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):